Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.54 |
| ▸ | CDC7 | O00311 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PIM1 | P11309 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723731 | 1.00 | ROCK1 (0.59) | ROCK1ROCK2CDC7MAP4K4PIM1 | |
| SCHEMBL27723699 | 0.85 | GPR142 (0.47) | ROCK1ROCK2CDC7MAP4K4PIM1 | |
| SCHEMBL4523467 | 0.85 | GPR142 (0.47) | ROCK1ROCK2CDC7MAP4K4PIM1 | |
| SCHEMBL4521922 | 0.85 | GPR142 (0.47) | ROCK1ROCK2CDC7MAP4K4PIM1 | |
| SCHEMBL4527537 | 0.85 | ROCK2 (0.54) | ROCK1ROCK2CDC7MAP4K4PIM1 | |
| SCHEMBL4525158 | 0.82 | ROCK2 (0.48) | ROCK1ROCK2CDK2AURKAPRKACA | |
| SCHEMBL27744384 | 0.82 | ROCK2 (0.48) | ROCK1ROCK2CDK2AURKAPRKACA | |
| SCHEMBL4630234 | 0.80 | BLM (0.44) | ROCK1ROCK2CLK4CYP3A4PRKACA | |
| SCHEMBL4529362 | 0.79 | LHCGR (0.42) | ROCK1ROCK2GSK3BCLK4CYP17A1 | |
| SCHEMBL4534345 | 0.79 | ROCK2 (0.72) | ROCK1ROCK2CDC7MAP4K4PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1922306-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007026920-A2 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885CDC7 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.